FTSE 100 stocks in focus: Unilever and GlaxoSmithKline

Unilever is keen to buy GlaxoSmithKline’s consumer healthcare business.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Writing last autumn about booming merger and acquisition (M&A) activity in the UK, I noted that City M&A specialists were forecasting there could be mega-deals to come.
 
And, in my last column of the year, highlighting seven FTSE 100 stocks to consider for 2022, I wrote of pharma giant GlaxoSmithKline: “I’ve long felt a break-up of GSK would unlock value for shareholders.”
 
These themes have come into sharp focus after a report in last weekend’s Sunday Times under the headline: ‘Unilever pursues £50bn bid for Glaxo’s consumer empire after rejection’.

What the companies said

In a weekend press release, Unilever confirmed it had made an approach, but added “there can be no certainty that any agreement will be reached.”
 
GSK said it rejected the proposal, because it “fundamentally undervalued the Consumer Healthcare business and its future prospects.”

CEOs under pressure

Unilever’s CEO, Alan Jope, and his counterpart at GSK, Emma Walmsley, have both been under pressure for a while from some vocal critics on their shareholder registers.
 
Jope has presided over a 5% decline in Unilever’s share price since he began the job in January 2019. During Walmsley’s tenure, which began in April 2017, GSK’s shares are down 2%. Both stocks have underperformed against their peer groups.


 
High-profile fund manager Terry Smith recently wrote: “Unilever seems to be labouring under the weight of a management which is obsessed with publicly displaying sustainability credentials at the expense of focusing on the fundamentals of the business.”

Meanwhile, activist investors over at GSK had wanted a formal sale process for the consumer health division, as opposed to the demerger the company is planning for later this year. They’ve also questioned whether Walmsley, who has a background in consumer goods, is the best candidate to lead a pure-play pharmaceuticals business.

A deal could still happen

Given Unilever’s lacklustre performance, and desire to accelerate a repositioning of its portfolio into higher growth categories, it’s easy to understand why Jope finds the idea of getting his hands on GSK’s consumer health division attractive.
 
Equally, with the £50bn offer being at only a modest premium to the valuation analysts have put on the business, it’s easy to see why GSK might feel the planned demerger is a better option.
 
Having said that, GSK (and minority partner Pfizer) can have no fundamental objection to a sale. After all, they’re both looking to exit the business anyway, via the demerger. And with Unilever clearly still interested in acquiring it, a deal at a higher price could yet go ahead.

A typical market reaction

The market reaction on Monday was to send GSK’s shares up 4% (to a level not seen since before the pandemic) and Unilever’s down 7% (to a multi-year low).
 
Positive sentiment towards a potential seller of a business and negative sentiment towards a potential acquirer is quite typical. In the case of the seller, the market sees prospects of that unlocking of value for the shareholders I mentioned. In the case of the buyer, it sees the risk and uncertainty that comes with an acquisition.

Taking a view

Despite the uplift in GSK’s share price, and a strong performance on a one-year view, I remain quite bullish on the stock. I think there’s still value to be unlocked here, whether by a sale or demerger.
 
And, after the slide in Unilever’s share price, and a weak performance on a one-year view, I see long-term value in the stock — even with the integration risk should the acquisition go ahead.
 
Terry Smith told his fund holders that “a company which feels it has to define the purpose of Hellmann’s mayonnaise has in our view clearly lost the plot.” But, nevertheless: “We continue to hold the shares because we think that its strong brands and distribution will triumph in the end.”
 
I don’t know if the latest turn of events will lead Smith to have a change of heart, but it’s undeniable that GSK’s consumer health brands would further enhance the strength of Unilever’s portfolio.

Foolish takeaway

I hark back to my column on booming UK M&A for a Foolish takeaway from Unilever’s approach to GSK. Trade buyers (and private equity houses) view a number of UK companies and their assets as more valuable than they’re being priced at in the market.
 
As such, I think this could be a great time for Foolish investors to buy in to some top UK businesses. This to reap the rewards of long-term ownership, but with an added bonus of a heightened possibility of a takeover at a premium price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Graham has no position in any of the shares mentioned in this article. The Motley Fool UK has recommended GlaxoSmithKline and Unilever.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

6.9% dividend yield! 2 cheap stocks to consider for a £1,380 passive income

Looking for a market-beating passive income? These FTSE 100 and FTSE 250 dividend stocks could provide a healthy second income…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

Potentially 34% undervalued, should I be watching the boohoo share price?

The boohoo share price has seen a rocky few years, but with signs that the economy is improving, could this…

Read more »

Investing Articles

Is the Amazon share price primed for a drop?

The Amazon share price has been on a tear for the last year, but can this trend continue? Gordon Best…

Read more »

Photo of a man going through financial problems
Investing Articles

Down 15% in a week! What’s gone wrong with the National Grid share price?

The National Grid share price isn't supposed to crash but now it has. Harvey Jones is wondering whether to take…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Taylor Wimpey just paid me £158.78. I’m aiming to turn that into a £100k yearly second income

Harvey Jones says small, regular dividend payments can turn a few pounds into a mighty second income, if he gives…

Read more »

A pastel colored growing graph with rising rocket.
Value Shares

These FTSE 250 shares are tipped to rise 14% to 18% in the next year!

Looking for the best FTSE 250 momentum shares to buy? Here are two that City analysts expect to soar in…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Lloyds’ share price is up 20% in 3 months! How high can it go?

Lloyds’ share price has ripped higher recently. Here, Edward Sheldon provides his view on the level it could potentially climb…

Read more »

Investing Articles

Why the Rolls-Royce share price could continue to outperform

The Rolls-Royce share price keeps moving forward, but this Fool thinks it's still behind where it ought to be after…

Read more »